This Article Full Text Full Text (PDF) Supplementary Data, Cahill, et al. Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Cahill, D. P. Articles by Louis, D. N. Search for Related Content PubMed PubMed Citation Articles by Cahill, D. P. Articles by Louis, D. N.

Loss of the Mismatch Repair Protein MSH6 in Human Glioblastomas Is Associated with Tumor Progression during Temozolomide Treatment

Authors' Affiliations: ¹ Molecular Pathology Unit, ² Neurosurgical Service, ³ Brain Tumor Center, and ⁴ Center for Cancer Research, Massachusetts General Hospital and Harvard Medical School; ⁵ Department of Biostatistics, Harvard School of Public Health, Boston, Massachusetts; and ⁶ Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, United Kingdom

Requests for reprints: David N. Louis, Pathology Service, Massachusetts General Hospital, 55 Fruit Street, Warren 2, Boston, MA 02114. Phone: 617-726-5690; Fax: 617-726-5684; E-mail: dlouis{at}partners.org.

Purpose: Glioblastomas are treated by surgical resection followed by radiotherapy [X-ray therapy (XRT)] and the alkylating chemotherapeutic agent temozolomide. Recently, inactivating mutations in the mismatch repair gene MSH6 were identified in two glioblastomas recurrent post-temozolomide. Because mismatch repair pathway inactivation is a known mediator of alkylator resistance in vitro, these findings suggested that MSH6 inactivation was causally linked to these two recurrences. However, the extent of involvement of MSH6 in glioblastoma is unknown. We sought to determine the overall frequency and clinical relevance of MSH6 alterations in glioblastomas.

Experimental Design: The MSH6 gene was sequenced in 54 glioblastomas. MSH6 and O⁶-methylguanine methyltransferase (MGMT) immunohistochemistry was systematically scored in a panel of 46 clinically well-characterized glioblastomas, and the corresponding patient response to treatment evaluated.

Results: MSH6 mutation was not observed in any pretreatment glioblastoma (0 of 40), whereas 3 of 14 recurrent cases had somatic mutations (P = 0.015). MSH6 protein expression was detected in all pretreatment (17 of 17) cases examined but, notably, expression was lost in 7 of 17 (41%) recurrences from matched post–XRT + temozolomide cases (P = 0.016). Loss of MSH6 was not associated with O⁶-methylguanine methyltransferase status. Measurements of in vivo tumor growth using three-dimensional reconstructed magnetic resonance imaging showed that MSH6-negative glioblastomas had a markedly increased rate of growth while under temozolomide treatment (3.17 versus 0.04 cc/mo for MSH6-positive tumors; P = 0.020).

Conclusions: Loss of MSH6 occurs in a subset of post–XRT + temozolomide glioblastoma recurrences and is associated with tumor progression during temozolomide treatment, mirroring the alkylator resistance conferred by MSH6 inactivation in vitro. MSH6 deficiency may therefore contribute to the emergence of recurrent glioblastomas during temozolomide treatment.